scholarly journals Indigofera suffruticosa: An Alternative Anticancer Therapy

2007 ◽  
Vol 4 (3) ◽  
pp. 355-359 ◽  
Author(s):  
Jeymesson Raphael Cardoso Vieira ◽  
Ivone Antônia de Souza ◽  
Silene Carneiro do Nascimento ◽  
Sônia Pereira Leite
Keyword(s):  
Solid Tumors ◽  
Antitumor Effect ◽  
Anticancer Agent ◽  
Anticancer Therapy ◽  
Control Group ◽  
Aqueous Extracts ◽  
Sarcoma 180 ◽  
Antitumor Effects ◽  
Mtt Method ◽  
Low Order

Indigofera suffruticosaMill (Fabeceae) occurs in the Northeast countryside and has intensive popular use in the treatment of infectious, inflammatory and other processes. The main aim of the present work was to investigate the cytotoxic and antitumor effects of aqueous extracts of leaves ofI. suffruticosaobtained by infusion and maceration as well as to evaluate the toxicological properties. Aqueous extracts did not exhibit cytotoxicity against HEp-2 (human epidermoid cancer cell) cell lines by MTT method. From the aqueous extract by infusion, the toxicological assay showed low order of toxicity. The antitumor effect of aqueous extracts by infusion (64.53%) and maceration (62.62%) against sarcoma 180 in mice at a dose of 50 mg kg−1(intraperitoneally), based on low order of toxicity was comparable to the control group, which showed 100% development. Considering the low order of toxicity and that it is highly effective in inhibiting growth of solid tumors, the aqueous extracts of leaves ofI. suffruticosamay be used as an alternative anticancer agent.

scholarly journals Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model

2020 ◽  
Vol 27 (1) ◽  
pp. 107327482092255 ◽  
Author(s):  
Shanshan Liu ◽  
Fei Wu ◽  
Yanling Zhang ◽  
Rongsheng Qin ◽  
Nengping Zhu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Oxygen Pressure ◽  
Antitumor Effect ◽  
Combined Treatment ◽  
Partial Oxygen Pressure ◽  
Control Group ◽  
Therapeutic Effects ◽  
Antitumor Effects ◽  
Tumor Inhibition ◽  
Partial Oxygen

Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are highly expressed in nasopharyngeal carcinoma; therefore, blocking the binding of VEGF and VEGFR may be a potential way to treat nasopharyngeal carcinoma. Apatinib inhibits tumor angiogenesis. Previous studies have suggested that treatment with apatinib has an antitumor effect on nasopharyngeal carcinoma. This study will investigate the effect of apatinib combined with radiotherapy. In this study, nude mice injected with CNE-2 nasopharyngeal carcinoma cells were randomly divided into 6 groups. Therapeutic effects were assessed by evaluating tumor inhibition rate, phosphorylation of VEGFR-2, CD31, partial oxygen pressure, and tumor metabolism. We found that the tumor inhibition of mice in the treated groups was better compared to that of the control group. In mice treated with apatinib alone, angiogenesis was prevented, and the tumor tissue partial oxygen pressure was reduced, thereby achieving an antitumor effect. Moreover, the tumor inhibitory effect of combined treatment was stronger than treatment with either apatinib or radiotherapy alone. Compared with monotherapy treatment, combined treatment better resisted angiogenesis. Apatinib combined with radiotherapy to treat nasopharyngeal carcinoma has synergistic effects, which may be related to enhanced antiangiogenesis.

Optical blood irradiation in improving the effectiveness of neoadjuvant polychemotherapy for breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12124-e12124
Author(s):  
Elena A. Sheiko ◽  
Alla Ivanovna Shikhlyarova ◽  
Larisa Nikolaevna Vashchenko ◽  
Stella Babieva
Keyword(s):  
Breast Cancer ◽  
Antitumor Effect ◽  
Treatment Effectiveness ◽  
Red Light ◽  
Anticancer Therapy ◽  
Incidence Rates ◽  
Control Group ◽  
Peripheral Vein ◽  
Blood Processing ◽  
Blood Irradiation

e12124 Background: Breast cancer (BC) incidence rates are increasing worldwide. Development of multicomponent programs, in particular polychemotherapy combined with technologies of quantum medicine, can help increase BC treatment effectiveness. The purpose of the study was to assess clinical efficacy of neoadjuvant polychemotherapy (PCT) modified with extracorporeal optical blood processing in BC. Methods: The study included 90 patients, mean age 48 years, with stage IIIB BC: nodular BC with secondary edema – 80 (88.8%) patients, edematous-infiltrative BC – 10 (11.2%) patients. Menstrual function was preserved in 20 (22.3%) patients; the other 70 (77.7%) women were menopausal. The control group (30 patients) received PCT with the total course doses of cytostatics: doxorubicin - 200 mg, 5-fluorouracil - 3000 mg, cyclophosphan - 100 mg, methotrexate - 100 mg. The main group (60 patients): 200 ml of blood from a peripheral vein was obtained into tubes with Glugicir, and then doxorubicin 50 mg/m2, methotrexate 25 mg/m2, 5-fluorouracil 750 mg/m2 and cyclophosphan 600 mg/m2 were added and incubated for 40 min at 37оC. The blood was continuously irradiated for 3 minutes using red light λ=0.67 µm, W=5 J/cm2. After that, the blood was transfused back to the patient intravenously. Each course included 3 procedures with a 3-day interval, and patients received 2-3 courses with a 3-week interval. Results: The assessment of neoadjuvant chemotherapy modified with extracorporeal optical blood processing showed increased rates of resectable BC by 2.8 times; an objective antitumor effect increased by 20%, and tumor growth rates reduced by 3.5 times. Conclusions: This technology can become an effective additional factor improving the effectiveness of anticancer therapy.

Boswellic acids synergize antitumor activity and protect against the cardiotoxicity of doxorubicin in mice bearing Ehrlich’s carcinoma

2015 ◽  
Vol 93 (8) ◽  
pp. 695-708 ◽  
Author(s):  
Shimaa A. Ali ◽  
Sawsan A. Zaitone ◽  
Yasser M. Moustafa
Keyword(s):  
Antitumor Activity ◽  
Solid Tumors ◽  
Elevated Serum ◽  
Control Group ◽  
Protective Effects ◽  
Antitumor Effects ◽  
Doxorubicin Treatment ◽  
Boswellic Acids ◽  
Ehrlich's Carcinoma ◽  
Group 2

This study aimed to test whether boswellic acids add to the antitumor effects of doxorubicin against solid tumors of Ehrlich’s ascites carcinoma (EAC) grown in mice, and to investigate the protective effects of boswellic acids against doxorubicin-induced cardiotoxicity. Sixty-four female Swiss albino mice bearing EAC solid tumors were distributed among 8 groups as follows: group 1, EAC control group; group 2, doxorubicin treatment group [mice were injected with doxorubicin (6 mg·(kg body mass)−1·week−1) for 3 weeks]; groups 3–5, these mice were treated with boswellic acids (125, 250, or 500 mg·kg−1·day−1), respectively; groups 6–8, these mice were treated with a combination of doxorubicin and boswellic acids (125, 250, or 500 mg·kg−1·day−1), respectively, for 3 weeks. The results indicated that boswellic acids synergized the antitumor activity of doxorubicin. Doxorubicin-treated mice showed elevated serum activities of lactate dehydrogenase and creatine kinase isoenzyme MB as well as cardiac malondialdehyde. Further, decreases in cardiac levels of reduced glutathione, superoxide dismutase, and catalase activities were observed. These effects were accompanied by an increase in cardiac expression of caspase 3. Thus, treatment with boswellic acids attenuated doxorubicin-evoked disturbances in the above-mentioned parameters, highlighting antioxidant and antiapoptotic activities. Therefore, boswellic acids could be potential candidates for ameliorating the cardiotoxicity of doxorubicin.

Antiurolithiatic effect of Cymbopogon Proximus, Alhagi Maurorum, on Sulfadimidine induced urolithiasis in male New Zealand rabbits

2019 ◽  
Vol 20 (1) ◽  
pp. 12-18
Author(s):  
Sameh El-Nabtity
Keyword(s):  
New Zealand ◽  
Intramuscular Injection ◽  
Negative Control Group ◽  
Negative Control ◽  
Control Group ◽  
Aqueous Extracts ◽  
Blood And Urine Samples ◽  
Group 2 ◽  
New Zealand Rabbits ◽  
Group 1

The present study aimed to investigate the prophylactic effect of Cymbopogon proximus and Alhagi maurorum on Sulfadimidine induced urolithiasis in rabbits . Thirty New Zealand male rabbits were allocated into six equal groups (each of five): Group (1) was used as a negative control. Group(2) were administered sulfadimidine (200mg/kg) by intramuscular injection.Groups(3) and (4) were administered sulfadimidine(200mg/kg) by intramuscular injection and 330mg/kg of Cymbopogon proximus alcoholic and aqueous extracts respectively orally.Groups(5) and (6) were administered sulfadimidine(200mg/kg) by intramuscular injection and 400mg/kg of Alhagi maurorum alcoholic and aqueous extracts respectively orally. The period of experiment was 10 days. Blood and urine samples were collected from rabbits on the 10th day. The results recorded a significant decrease in serum creatinine, urea, uric acid and crystalluria in Cymbopogon proximus and Alhagi maurorum groups compared to sulfadimidine treated group.We conclude that Cymbopogon proximus and Alhagi maurorum have a nephroprotective and antiurolithiatic effects against sulfadimidine induced crystalluria.

scholarly journals Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Dehua Lu ◽  
Yanpu Wang ◽  
Ting Zhang ◽  
Feng Wang ◽  
Kui Li ◽  
...  
Keyword(s):  
T Cells ◽  
T Lymphocytes ◽  
Solid Tumors ◽  
Cytotoxic T Lymphocytes ◽  
Pet Imaging ◽  
Stage Migration ◽  
Cell Transfer ◽  
Tumor Infiltration ◽  
Antitumor Effects

Abstract Background Adoptive T cell transfer-based immunotherapy yields unsatisfactory results in the treatment of solid tumors, partially owing to limited tumor infiltration and the immunosuppressive microenvironment in solid tumors. Therefore, strategies for the noninvasive tracking of adoptive T cells are critical for monitoring tumor infiltration and for guiding the development of novel combination therapies. Methods We developed a radiolabeling method for cytotoxic T lymphocytes (CTLs) that comprises metabolically labeling the cell surface glycans with azidosugars and then covalently conjugating them with 64Cu-1,4,7-triazacyclononanetriacetic acid-dibenzo-cyclooctyne (64Cu-NOTA-DBCO) using bioorthogonal chemistry. 64Cu-labeled control-CTLs and ovalbumin-specific CTLs (OVA-CTLs) were tracked using positron emission tomography (PET) in B16-OVA tumor-bearing mice. We also investigated the effects of focal adhesion kinase (FAK) inhibition on the antitumor efficacy of OVA-CTLs using a poly(lactic-co-glycolic) acid (PLGA)-encapsulated nanodrug (PLGA-FAKi). Results CTLs can be stably radiolabeled with 64Cu with a minimal effect on cell viability. PET imaging of 64Cu-OVA-CTLs enables noninvasive mapping of their in vivo behavior. Moreover, 64Cu-OVA-CTLs PET imaging revealed that PLGA-FAKi induced a significant increase in OVA-CTL infiltration into tumors, suggesting the potential for a combined therapy comprising OVA-CTLs and PLGA-FAKi. Further combination therapy studies confirmed that the PLGA-FAKi nanodrug markedly improved the antitumor effects of adoptive OVA-CTLs transfer by multiple mechanisms. Conclusion These findings demonstrated that metabolic radiolabeling followed by PET imaging can be used to sensitively profile the early-stage migration and tumor-targeting efficiency of adoptive T cells in vivo. This strategy presents opportunities for predicting the efficacy of cell-based adoptive therapies and for guiding combination regimens. Graphic Abstract

scholarly journals 150 GAIA-102: a new class off-the-shelf allogeneic NK-like cells that can eliminate solid tumors

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A163-A163
Author(s):  
Yui Harada ◽  
Yoshikazu Yonemitsu
Keyword(s):  
Nk Cells ◽  
Solid Tumors ◽  
Tumor Cells ◽  
Adoptive Immunotherapy ◽  
Nk Cell ◽  
Peritoneal Dissemination ◽  
Checkpoint Inhibitors ◽  
Antitumor Effects ◽  
Car T

BackgroundCancer immunotherapy has been established as a new therapeutic category since the recent success of immune checkpoint inhibitors and a type of adoptive immunotherapy, namely chimeric antigen receptor-modified T cells (CAR-T). Although CAR-T demonstrated impressive clinical results, serious adverse effects (cytokine storm and on-target off-tumor toxicity) and undefined efficacy on solid tumors are important issues to be solved. We’ve developed a cutting-edge, simple, and feeder-free method to generate highly activated and expanded human NK cells from peripheral blood (US9404083, PCT/JP2019/012744, PCT/JP2020/012386), and have been conducting further investigation why our new type of NK cells, named as GAIA-102, are so effective to kill malignant cells.MethodsCryopreserved PBMCs purchased from vendors were mixed and processed by using LOVO and CliniMACS® Prodigy (automated/closed systems). CD3+ and CD34+ cells were depleted, and the cells were cultured with high concentration of hIL-2 and 5% UltraGRO® for 14 days in our original closed system. Then, we confirmed the expression of surface markers, CD107a mobilization and cell-mediated cytotoxicity against various tumor cells and normal cells with or without monoclonal antibody drugs in vitro and antitumor effects against peritoneal dissemination model using SKOV3 in vivo.ResultsImportantly, we’ve found that our GAIA-102 exhibited CD3-/CD56bright/CD57- immature phenotype that could kill various tumor cells efficiently from various origins, including Raji cells that was highly resistant to NK cell killing. More importantly, massive accumulation, retention, infiltration and sphere destruction by GAIA-102 were affected neither by myeloid-derived suppressor cells nor regulatory T-lymphocytes. GAIA-102 was also effective in vivo to murine model of peritoneal dissemination of human ovarian cancer; thus, these findings indicate that GAIA-102 has a potential to be an ‘upward compatible’ modality over CAR-T strategy, and would be a new and promising candidate for adoptive immunotherapy against solid tumors.ConclusionsWe now just started GMP/GCTP production of this new and powerful NK cells and first-in-human clinical trials in use of GAIA-102 will be initiated on 2021.Ethics ApprovalThe animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Kyushu University (approval nos. A30-234-0 and A30-359-0).

scholarly journals Murine hepatoma treatment with mature dendritic cells stimulated by Trichinella spiralis excretory/secretory products

Parasite ◽  
2020 ◽  
Vol 27 ◽  
pp. 47
Author(s):  
Jing Ding ◽  
Xiaolei Liu ◽  
Bin Tang ◽  
Xue Bai ◽  
Yang Wang ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Tumor Growth ◽  
Antitumor Effect ◽  
Trichinella Spiralis ◽  
Critical Role ◽  
Tumor Model ◽  
Control Group ◽  
Tumor Inhibition ◽  
Significant Difference ◽  
Secretory Products

Excretory/Secretory Products (ESPs) of the nematode Trichinella spiralis contain antitumor-active substances that inhibit tumor growth. Mature dendritic cells (DCs) play a critical role in the antitumor immunity of the organism. As pathogen-derived products, it ought to be discussed whether T. spiralis ESPs will reduce the antitumor effect of mature DCs from the host before it is applied to patients’ tumors. Therefore, the aim of this work was to evaluate the immunological effect of DCs stimulated by T. spiralis ESPs in H22 tumor-bearing mice. H22 tumor model mice in this study were randomly divided into four groups according to the treatment: PBS control group, ESP group, DCs group, and DCs stimulated with T. spiralis ESP (ESP+DCs group). The antitumor effect was evaluated by tumor inhibition rate and cytokine detection using ELISA. The results showed significant inhibition in tumor growth in the ESP+DCs, DCs and ESP groups when compared with the PBS control group (p < 0.01, p < 0.01, and p < 0.05, respectively). However, no significant difference was observed on tumor inhibition rates between the ESP+DCs and DCs groups. The decrease in IL-4, IL-6, and IL-10, and the increase in IFN-γ between the DCs and ESP+DCs groups were also not significant. Therefore, DCs stimulated by ESP did not reduce the antitumor effect of mature DCs, which demonstrated that the T. spiralis ESP would not affect the antitumor effect of mature DCs by modulating the immune response of the host, and that ESPs are safe in antitumor immunology when applied in a tumor model mice.

POTENTIAL DIURETIC EFFECT OF CURCUMA AMADA ROXB. RHIZOME EXTRACTS

INDIAN DRUGS ◽  
2013 ◽  
Vol 50 (04) ◽  
pp. 34-38
Author(s):  
P Bommannavar ◽  
◽  
K. Patil
Keyword(s):  
Aqueous Extract ◽  
Urine Volume ◽  
Control Group ◽  
Aqueous Extracts ◽  
Diuretic Activity ◽  
Curcuma Amada ◽  
Male Wistar Rats ◽  
Total Urine ◽  
Dose Dependent Increase ◽  
Dose Dependent

The present study was undertaken to establish the diuretic activity of alcoholic and aqueous extract of dried rhizomes of Curcuma amada Roxb in rats. Alcoholic and aqueous extracts of rhizomes were administered to experimental male Wistar rats orally at doses of 250 and 500 mg/kg and compared with furosemide (10 mg/kg) as the reference standard. The parameters measured for diuretic activity were total urine volume, urine electrolyte concentration such as sodium, potassium and chloride have been evaluated. The rats treated with alcoholic and aqueous extract of Curcuma amada in a dose of 250 and 500 mg/kg showed higher urine output when compared to the respective control. Both alcoholic and aqueous extracts have showed a significant dose-dependent increase in the excretion of electrolytes when compared to the control group. The result indicates that alcoholic and aqueous extract is an effective natriuretic and kaliuretic diuretic, which supports the traditional claim about the Curcuma amada Roxb being used as diuretics.

Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2506-2506
Author(s):  
Anthony W. Tolcher ◽  
James Andrew Reeves ◽  
Meredith McKean ◽  
Bartosz Chmielowski ◽  
Joseph Thaddeus Beck ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Performance Status ◽  
Nerve Sheath Tumor ◽  
Advanced Solid Tumors ◽  
Antitumor Effects ◽  
Ecog Performance Status ◽  
Multiple Tumor

2506 Background: Alrizomadlin (APG-115) restores TP53 function, activating p53-mediated apoptosis in tumor cells with wild-type TP53 and/or MDM2 amplification. Alrizomadlin also functions as a host immunomodulator and hence may restore antitumor activity in pts with cancers failing PD-1/PD-L1 blockade. Methods: This US multicenter trial assessed alrizomadlin combined with pembrolizumab in pts with unresectable/metastatic melanoma or advanced solid tumors that had failed I-O drugs; or pts with malignant peripheral nerve sheath tumor (MPNST), liposarcoma, or ATM mutant solid tumors that had failed any standard therapy. Eligible pts had ECOG performance status of 0-2 and no CNS metastases. The phase II study cohorts included pts with melanoma, NSCLC, solid tumor with ATM mutation, well-differentiated/dedifferentiated liposarcoma, urothelial carcinoma, and MPNST. Alrizomadlin was administered orally at 150 mg once every other day for 2 consecutive weeks with 1 week off and pembrolizumab at 200 mg via IV infusion for 30 minutes on Day 1 of a 21-day cycle. Results: As of December 25, 2020, 84 pts had been treated in 6 cohorts: melanoma (n = 26), NSCLC (n = 23), ATM mutation (n = 9), liposarcoma (n = 14), urothelial (n = 9), and MPNST (n = 3). In the PD-1/PD-L1 inhibitor-failed melanoma cohort, there was 1 confirmed partial response (PR) out of 5 pts with uveal melanoma, 2 PR (1 confirmed and 1 unconfirmed) of 5 pts with mucosal melanoma, and 1 confirmed PR of 11 pts with cutaneous melanoma. ORR in the melanoma cohort was 17.4% (4/23 evaluable pts), and the disease control rate was 60.9% (14/23). In the MPNST cohort, 1 of 3 pts had an unconfirmed ongoing PR. In I-O drug-failed NSCLC (n = 14 evaluable) and urothelial (n = 5 evaluable) cohorts, each reported 1 confirmed PR. Common treatment (alrizomadlin or pembrolizumab)-related adverse events (TRAEs) (≥ 10%) were nausea (63.1%), thrombocytopenia (36.9%), vomiting (33.3%), fatigue (31.0%), decreased appetite (27.4%), diarrhea (21.4%), neutropenia (15.4%), and anemia (11.9%). Grade ≥ 3 TRAEs (≥ 5%) included thrombocytopenia (20.2%), neutropenia (14.2%), and anemia (8.3%). Eleven pts discontinued treatment due to AEs: 5 were treatment related, including 2 grade 4 thrombocytopenia, and 1 each of grade 2 vomiting, grade 2 fatigue, and grade 2 posterior reversible encephalopathy syndrome (PRES). Three treatment-related SAEs were PRES, pyrexia, and asthenia. Conclusions: Alrizomadlin combined with pembrolizumab is well tolerated and may restore antitumor effects in pts with cancer resistant to or intolerant of I-O drugs, as suggested by preliminary antitumor activities in multiple tumor types. Internal study identifiers: APG-115-US-002; Keynote MK-3475-B66. Clinical trial information: NCT03611868.

scholarly journals Efficacy of Mahogany Bark Aqueous Extracts and Exposure to Solar Heat for Treatment of Potato Tuber Soft Rot Caused by Erwinia Carotovora Ssp. Carotovora

2010 ◽  
Vol 50 (3) ◽  
pp. 393-397
Author(s):  
Bulus Bdliya ◽  
Peter Abraham
Keyword(s):  
Potato Tuber ◽  
Plant Extract ◽  
Erwinia Carotovora ◽  
Soft Rot ◽  
Bark Extract ◽  
Control Group ◽  
Aqueous Extracts ◽  
Solar Heat ◽  
Severity Of The Disease ◽  
Tuber Treatment

Efficacy of Mahogany Bark Aqueous Extracts and Exposure to Solar Heat for Treatment of Potato Tuber Soft Rot Caused byErwinia CarotovoraSsp.CarotovoraThe efficacy of combining tuber treatment with mahogany bark aqueous extracts and exposure to solar heat for the control of potato tuber soft rot was investigated. Artificially inoculated potato tubers were treated with mahogany bark aqueous extracts and exposed to solar heat for zero, one, two and three hours. The results showed that tuber treatment with the plant extract followed by exposure to solar heat significantly reduced the incidence and severity of tuber soft rot compared to the control group. However, the highest reduction in the incidence and severity of the disease was recorded on tubers treated with the plant extract and incubated immediately after treatment (no exposure to solar heat). This suggests that the plant extract is more effective at lower than higher temperatures. Potato tuber losses due to soft rot could therefore be managed by tuber treatment with mahogany bark extract and no exposure to solar heat.

Sign in / Sign up

Export Citation Format

Share Document